This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.

Adacel® is only indicated for patients 10-64 years of age.2

*Tetanus, diphtheria, and acellular pertussis.
U.S. Food and Drug Administration

Adacel is a registered trademark of Sanofi Pasteur group, and its subsidiaries.

BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tdap

References:

  1. Prescribing Information for BOOSTRIX.
  2. Prescribing Information for Adacel.
  3. American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.